Skip to main content

Table 5 Disease activity at 12 months for patients in DAS28 remission at 6 months.

From: Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register

Disease activity at 12 months BIOL, n (%) CON, n (%)
   In remission (DAS28 <2.6) 56 (54.9%) 18 (58.1%)
   Low disease activity (DAS28 <3.2) 17 (16.7%) 7 (22.6%)
   Moderate or high disease activity (DAS28 >3.2) 29 (28.4%) 6 (19.4%)
Total 102 31
  1. BIOL, patients treated with biologics; CON, patients receiving conventional DMARD treatment (control group); DAS28, disease activity score based on 28 joint counts.